Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 7/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.39 |
| ▸ | IGF1R | P08069 | 5/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1896630 | 0.95 | INSR (0.40) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL1894442 | 0.93 | IGF1R (0.39) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL4323717 | 0.92 | IGF1R (0.41) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL1894802 | 0.92 | IGF1R (0.38) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL1895342 | 0.92 | INSR (0.41) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL1433771 | 0.92 | INSR (0.41) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL1433772 | 0.92 | INSR (0.41) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL1433425 | 0.88 | INSR (0.42) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL1433424 | 0.88 | INSR (0.42) | INSRALKIGF1RAURKAAURKB | |
| SCHEMBL1893910 | 0.88 | INSR (0.42) | INSRALKIGF1RAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809337-B2 | Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-08-19 | — | — | US | claimed |
| US-20130203770-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-08-08 | — | — | US | claimed |
| US-20110118278-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-19 | — | — | US | claimed |
| US-8809337-B2 | Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-08-19 | — | — | US | disclosed |
| US-20130203770-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-08-08 | — | — | US | disclosed |
| US-20110118278-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203770-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | DMPK, DCK, MAP3K19 | INSR 1921/4885ALK 158/4885IGF1R 1797/4885 |
| US-20110118278-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | DMPK, DCK, MAP3K19 | INSR 1921/4885ALK 158/4885IGF1R 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.